Sonnet Shareholders Approve Merger Creating HYPE Crypto Treasury

Sonnet BioTherapeutics’ shareholders have approved a merger with Hyperliquid Strategies and Rorschach I, creating a publicly traded HYPE-focused crypto treasury vehicle. This agreement shifts focus towards digital assets as Sonnet becomes a wholly-owned subsidiary of the new entity. Involved parties include Sonnet BioTherapeutics, Hyperliquid Strategies, and Rorschach I. Together, they formed Hyperliquid Strategies Inc, targeting up to $1 billion in HYPE-centric digital asset reserves. This positions Hyperliquid as a pivotal HYPE-digital asset treasury reserve company. “The deal was approved by Sonnet stockholders on December 2, 2025,” according to a company notice from StockTitan. This reflects the strategic pivot towards HYPE cryptocurrency assets as highlighted by the firms involved.

The merger is expected to impact digital asset markets significantly, pivoting Sonnet’s role to focus on HYPE cryptocurrency. This SEC-reviewed merger marks a rare shift for a Nasdaq-listed company into crypto-treasury management. The financial implications include establishing a $305 million treasury composed of cash and HYPE tokens, with plans for a $1 billion stock offering. This SEC-reviewed structure positions the merged entity as a large corporate holder of HYPE.

Analysts anticipate competitive positioning within the HYPE ecosystem may shift, given the growing attention from Nasdaq-listed companies. Historical precedents for such mergers remain rare in the digital asset domain. The merger may influence regulatory developments by serving as a blueprint for other public firms contemplating digital asset reserves. Consequently, markets will observe how this strategic commercialization unfolds within the HYPE ecosystem.